Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00813514|
Recruitment Status : Withdrawn
First Posted : December 23, 2008
Last Update Posted : November 21, 2014
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease.
For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.
|Condition or disease||Intervention/treatment||Phase|
|Choroidal NeoVascularization Age-Related Macular Degeneration||Genetic: VEGF genotyping||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV?|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Open longitudinal study with observer masked analysis
Genetic: VEGF genotyping
blood sample for gene analysis
- Visual acuity using ETDRS charts [ Time Frame: 2 x 5 minutes ]
- Central retinal thickness (Optical coherence tomography) [ Time Frame: 2 x 20 minutes ]
- VEGF genotyping [ Time Frame: 1 week ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00813514
|Department of Clinical Pharmacology, Medical University of Vienna|
|Principal Investigator:||Leopold Schmetterer, Prof. Dr.||Department of Clinical Pharmacology|